Guest: Harry Paul Erba, MD, PhD

For several decades, therapy for acute myeloid leukemia (AML) was rather straightforward. But now that we have a deeper understanding of the pathogenesis of AML, this has led to the identification of potential therapeutic targets that give us options in addition to standard intensive chemotherapy, as Dr. Harry Erba explains.

BCL2-US-00026-MC
Version 2.0, Approved November 2020